Beijing Succeeder Technology Inc.

Shanghai Stock Exchange 688338.SS

Beijing Succeeder Technology Inc. Revenue for the year ending December 31, 2023: USD 38.80 M

Beijing Succeeder Technology Inc. Revenue is USD 38.80 M for the year ending December 31, 2023, a 17.03% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Beijing Succeeder Technology Inc. Revenue for the year ending December 31, 2022 was USD 33.16 M, a -12.18% change year over year.
Beijing Succeeder Technology Inc. Revenue for the year ending December 31, 2021 was USD 37.76 M, a 10.82% change year over year.
Beijing Succeeder Technology Inc. Revenue for the year ending December 31, 2020 was USD 34.07 M, a 3.35% change year over year.
Beijing Succeeder Technology Inc. Revenue for the year ending December 31, 2019 was USD 32.97 M, a 13.31% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688338.SS

Beijing Succeeder Technology Inc.

CEO	Mr. Hai Wang
IPO Date	Aug. 6, 2020
Location	China
Headquarters	Tower 1A
Employees	296
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Medical Instruments Pharmaceuticals

Description

Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. Its products include coagulation analyzers and reagents, blood rheology analyzers, ESR analyzers, and platelet aggregation analyzers. The company was founded in 2003 and is headquartered in Beijing, China.

Key trends

Past 5 years